MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.6419
-0.0481
-6.97%
Opening 09:33 02/09 EST
OPEN
0.6693
PREV CLOSE
0.6900
HIGH
0.6693
LOW
0.6403
VOLUME
36.96K
TURNOVER
--
52 WEEK HIGH
4.650
52 WEEK LOW
0.5480
MARKET CAP
4.49M
P/E (TTM)
-0.2998
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APRE last week (0202-0206)?
Weekly Report · 7h ago
*Aprea Therapeutics Appoints Eugene Kennedy as Chief Medical Advisor
Dow Jones · 5d ago
Aprea Therapeutics Names Eugene Kennedy as Chief Medical Advisor
Reuters · 5d ago
Top Executive Makes Bold Insider Move at Aprea Therapeutics
TipRanks · 6d ago
Aprea Therapeutics Inc. President and CEO Gilad Oren Reports Acquisition of Common Shares
Reuters · 6d ago
Aprea Therapeutics CFO John P. Hamill Acquires Common Shares
Reuters · 6d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 6d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 02/02 12:05
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.